Scarica l'app Stockscreener
45.37
1.24%
-0.57
Dopo l'orario di chiusura:
45.17
-0.20
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$45.94
Aprire:
$46.635
Volume 24 ore:
10.21M
Relative Volume:
1.24
Capitalizzazione di mercato:
$17.99B
Reddito:
$1.94B
Utile/perdita netta:
$-2.82B
Rapporto P/E:
-6.2478
EPS:
-7.2617
Flusso di cassa netto:
$-2.08B
1 W Prestazione:
-10.57%
1M Prestazione:
-9.31%
6M Prestazione:
+67.05%
1 anno Prestazione:
+67.85%
Intervallo 1D:
$43.68
$48.40
Intervallo di 1 settimana:
$43.68
$51.36
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.37 | 17.99B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals - Yahoo Finance
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges By GuruFocus - Investing.com Canada
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges - GuruFocus
Moderna (MRNA) Reports Strong Q1 2026 Performance with $400 Million Revenue - GuruFocus
Moderna, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) - Stock Titan
Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales - The Economic Times
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. - Barron's
Sector Update: Health Care Stocks Softer Friday Afternoon - Moomoo
Moderna, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRNA) 2026-05-01 - Seeking Alpha
Moderna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com - Investing.com Canada
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - The Globe and Mail
Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings - Proactive financial news
[144] Moderna, Inc. SEC Filing - Stock Titan
BofA raises Moderna stock price target to $32 on Q1 beat - Investing.com India
Moderna Sales Triple To $389 Million As Shares Rise 5.4% - GuruFocus
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook - Seeking Alpha
Why Is Moderna Stock Falling Friday?Moderna (NASDAQ:MRNA) - Benzinga
Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates - marketscreener.com
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround - TechStock²
Moderna beats revenue expectations with $389M, but litigation dogs earnings - BioSpace
Moderna Q1 Earnings Call Highlights - MarketBeat
Moderna tops revenue estimates on stronger international COVID vaccine sales - Yahoo! Finance Canada
Moderna Q1 2026 slides: revenue surges 260%, litigation weighs By Investing.com - Investing.com India
Transcript : Moderna, Inc., Q1 2026 Earnings Call, May 01, 2026 - marketscreener.com
Moderna Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Moderna Q1 2026 revenue beats expectations By Investing.com - Investing.com India
Earnings call transcript: Moderna Q1 2026 revenue beats expectations - Investing.com
Moderna Q1 2026 earnings beat on international COVID vaccine sales - Yahoo Finance
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates - Investing News Network
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars - Yahoo Finance
Moderna (MRNA) Stock Jumps 8% After Q1 Earnings Beat - CoinCentral
Moderna Up Over 6% in Pre-Market Trading - Moomoo
MRNA Stock Rises Pre-Market: Moderna Bets On US Comeback With Flu Vaccine Pipeline - Stocktwits
Moderna beats Q1 estimates and reaffirms full-year guidance - Sherwood News
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna Inc (NASDAQ:MRNA) Surges Past Q1 Estimates on International Strength - ChartMill
Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL) - marketscreener.com
Moderna beats revenue expectations despite wider loss - Investing.com
Moderna Q1 Loss Widens, Revenue Rises; Reiterates 2026 Revenue Outlook - marketscreener.com
Moderna stock jumps after Q1 2026 beat (MRNA:NASDAQ) - Seeking Alpha
Moderna: Q1 Earnings Snapshot - KING5.com
EU clears Moderna's flu-COVID shot as Q1 loss hits $1.3B - Stock Titan
Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimat - The Economic Times
Earnings Flash (MRNA) Moderna Posts Q1 Loss $3.40 a Share, vs. FactSet Est of $4.45 Loss - marketscreener.com
Moderna reports Q1 EPS of $ -3.40 - marketscreener.com
Moderna Reports Higher Revenue but Posts a Loss - WSJ
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Option Exercise |
30.96 |
13,885 |
429,880 |
73,574 |
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):